Literature DB >> 9196361

Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis.

P Vic1, S Ategbo, F Gottrand, V Launay, G A Loeuille, J C Elian, D Druon, J P Farriaux, D Turck.   

Abstract

OBJECTIVE: To evaluate the short term effects on nutritional status of home intravenous anti-pseudomonas antibiotic courses in cystic fibrosis (CF) patients chronically colonised with Pseudomonas aeruginosa.
DESIGN: A prospective study involving 38 CF patients, mean age 10.9 (SD 4.3) years (range 4.3 to 22.2 years), presenting with pulmonary exacerbations of P aeruginosa infection. The patients received a 14 day antibiotic course of intravenous ceftazidime (200 mg/kg/day) and either amikacin (35 mg/kg/day) or tobramycin (15 mg/kg/day). Nutritional evaluation on days 1 and 14 involved measurements of weight, weight/height ratio (per cent of predicted value), energy intake (per cent of recommended daily allowances), serum prealbumin, and body composition assessed by two methods: bioelectrical analysis (BIA) and skinfold anthropometry. The non-parametric Wilcoxon t test was used for statistical analysis, with a Bland-Altman plot to assess the degree of agreement between the two methods of evaluating body composition.
RESULTS: Weight increased by 1.0 (0.8) kg (p < 0.001); weight/height increased from 94.4(12.2)% to 98(12.7)% (p < 0.001), energy intake from 107(32)% to 119(41)% (p < 0.02), and prealbumin from 183 (63) to 276 (89) mg/l (p < 0.001). Fat mass increased by 0.8 (1.0) kg (p < 0.001), without any significant change in fat-free mass. The limits of agreement between BIA and anthropometry were -0.7 kg and +1.1 kg.
CONCLUSIONS: Antibiotic courses allow an improvement in nutritional status in CF patients, with a gain in fat mass.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196361      PMCID: PMC1717178          DOI: 10.1136/adc.76.5.437

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  21 in total

Review 1.  Nutritional requirements in cystic fibrosis: a review.

Authors:  J A Dodge
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988       Impact factor: 2.839

2.  Energy expenditure of patients with cystic fibrosis.

Authors:  N Vaisman; P B Pencharz; M Corey; G J Canny; E Hahn
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406

3.  Determination of body composition of children from skinfold measurements.

Authors:  C G Brook
Journal:  Arch Dis Child       Date:  1971-04       Impact factor: 3.791

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Relative underweight in cystic fibrosis and its prognostic value.

Authors:  R Kraemer; A Rüdeberg; B Hadorn; E Rossi
Journal:  Acta Paediatr Scand       Date:  1978-01

Review 6.  The impact of nutrition in cystic fibrosis: a review.

Authors:  K J Gaskin
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988       Impact factor: 2.839

7.  The assessment of the amount of fat in the human body from measurements of skinfold thickness.

Authors:  J V Durnin; M M Rahaman
Journal:  Br J Nutr       Date:  1967-08       Impact factor: 3.718

8.  Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Authors:  M Szaff; N Høiby; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1983-09

9.  Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover.

Authors:  R W Shepherd; T L Holt; G Cleghorn; L C Ward; A Isles; P Francis
Journal:  Am J Clin Nutr       Date:  1988-08       Impact factor: 7.045

10.  Are bioelectric impedance measurements valid in patients with cystic fibrosis?

Authors:  D Borowitz; K Conboy
Journal:  J Pediatr Gastroenterol Nutr       Date:  1994-05       Impact factor: 2.839

View more
  1 in total

Review 1.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Authors:  Matthew N Hurley; Andrew P Prayle; Patrick Flume
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.